Nemluvio (Nemolizumab)

Nemolizumab, the active ingredient in Nemluvio, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It is designed to modulate immune pathways that contribute to chronic itch and skin inflammation in certain dermatologic conditions. GNH USA supplies Nemluvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nemluvio targets the interleukin‑31 pathway, which is implicated in pruritic dermatologic disorders. It is clinically employed for the following indications: - Atopic dermatitis (moderate‑to‑severe): reduces itch intensity and improves skin lesions. - Prurigo nodularis: alleviates persistent nodular itching and promotes lesion resolution. - Chronic pruritus associated with other inflammatory skin diseases: provides itch relief when conventional therapies are insufficient.

Nemluvio may be associated with a range of adverse reactions. The frequency and severity vary among patients.

Common Side Effects: - Injection site pain or erythema. - Nasopharyngitis or upper respiratory tract infection. - Headache. - Fatigue. - Gastrointestinal discomfort. - Transient increase in eosinophil count.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Serious infections, including opportunistic pathogens. - Neutropenia or other hematologic abnormalities. - Autoimmune phenomena such as lupus‑like syndrome. - Cardiovascular events (rare).

When prescribing Nemluvio, clinicians should consider several safety measures: - Infection risk: monitor patients for signs of infection and postpone treatment if active infection is present. - Hypersensitivity: assess history of allergic reactions to monoclonal antibodies before initiation. - Immunocompromised status: use with caution in patients receiving other immunosuppressive therapies. - Vaccination: avoid live vaccines during treatment and for several weeks after the last dose. - Pregnancy and lactation: discuss potential risks with women of childbearing potential; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Nemluvio’s biologic nature warrants attention to concomitant therapies that may alter its safety or efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent administration can lead to uncontrolled infection. - Known severe hypersensitivity to other monoclonal antibodies targeting IL‑31 pathways.

Moderate Interactions (Monitor Closely): - Other immunosuppressants (e.g., systemic corticosteroids, methotrexate): may increase infection susceptibility. - Antiviral or antifungal agents that affect immune function: monitor for additive immunosuppression. - Cytokine‑modulating agents: assess for overlapping adverse effect profiles.